Rialto Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Rialto Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-772	Closed	-$3.16K	–	1790
2025 Q4	$3.16K	Hold	772	–	–	﹤0.01%	596
2025 Q3	$3.77K	Hold	772	–	–	﹤0.01%	521
2025 Q2	$3.91K	Hold	772	–	–	﹤0.01%	487
2025 Q1	$4.08K	Hold	772	–	–	﹤0.01%	467
2024 Q4	$5.22K	Buy	+772	New	+$5.19K	﹤0.01%	454

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rialto Wealth Management's RXRX Position: Q1 2026 in Review

Rialto Wealth Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 772 shares — an estimated $3.16K sold.

Rialto Wealth Management first reported a position in RXRX in Q4 2024 and held it in 5 quarters. The position peaked at $5.22K in Q4 2024. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Rialto Wealth Management reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Rialto Wealth Management sold 772 Recursion Pharmaceuticals shares in Q1 2026, an estimated $3.16K.
Rialto Wealth Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 5 quarters.
Rialto Wealth Management's Recursion Pharmaceuticals position peaked at $5.22K in Q4 2024.
335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Rialto Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.